Paul Vincke, President of the European Healthcare Fraud and Corruption Network, and a civil servant at the Ministry of Health in Belgium, outlines recent developments in anti-corruption and bribery legislation in the pharmaceuticals industry.

The UK Bribery Bill: Issued in April 2010 is due to come into force in April 2011. As this is one of the biggest developments in this area for years, we ask Vincke how he interprets the delays in enforcing this legislation, what the implications of the Act will be on the way companies conduct their business in the future, and why is it important to revise compliance policy even in advance of the UK Bribery Act enforcement.

The Global Picture: The unique challenges the life sciences industry faces in relation to Bribery and Corruption; Whether the role of corporate whistle-blowing has changed in corporate bribery cases and if so, how; What companies and industries must do in order to achieve the best outcomes in trials and the most important things to keep in mind when developing and monitoring a compliance policy. Haven’t got the technology to listen to the podcast? Read the interview here Bribery and Corruption in Pharma: President of the EHFCN Speaks Out.

[inlinead]